CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $679,000 | -19.4% | 5,570 | +1.3% | 0.00% | 0.0% |
| Q4 2020 | $842,000 | +83.0% | 5,500 | 0.0% | 0.00% | – |
| Q3 2020 | $460,000 | +13.9% | 5,500 | 0.0% | 0.00% | – |
| Q2 2020 | $404,000 | +73.4% | 5,500 | 0.0% | 0.00% | – |
| Q1 2020 | $233,000 | -30.4% | 5,500 | 0.0% | 0.00% | – |
| Q4 2019 | $335,000 | +48.9% | 5,500 | 0.0% | 0.00% | – |
| Q3 2019 | $225,000 | +10.8% | 5,500 | +27.9% | 0.00% | – |
| Q2 2019 | $203,000 | +31.8% | 4,300 | 0.0% | 0.00% | – |
| Q1 2019 | $154,000 | +22.2% | 4,300 | -2.3% | 0.00% | – |
| Q4 2018 | $126,000 | -11.3% | 4,400 | +37.5% | 0.00% | – |
| Q3 2018 | $142,000 | -24.5% | 3,200 | 0.0% | 0.00% | – |
| Q2 2018 | $188,000 | +46.9% | 3,200 | +14.3% | 0.00% | – |
| Q1 2018 | $128,000 | +70.7% | 2,800 | -12.5% | 0.00% | – |
| Q4 2017 | $75,000 | – | 3,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |